Welcome to our dedicated page for GB Sciences news (Ticker: GBLX), a resource for investors and traders seeking the latest updates and insights on GB Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GB Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GB Sciences's position in the market.
GB Sciences, Inc. (OTCQB:GBLX) has partnered with Purisys, LLC to supply ultra-high purity cannabinoids for its cannabinoid-containing optimized therapeutic mixtures (OTM). This strategic alliance aims to enhance the standardization and quality of GB Sciences' pharmaceutical products, particularly essential for preclinical and clinical trials. GB Sciences holds a robust intellectual property portfolio with 5 US and 3 international patents, alongside multiple pending applications targeting various medical conditions. The lead program focuses on developing a therapeutic for Parkinson's disease.
GB Sciences (OTCQB:GBLX) filed a provisional patent for its innovative drug discovery platform, integrating data analytics and machine learning to identify effective plant-derived therapeutics. This platform aims to expedite the development of novel combination drugs, enhancing research efficiency and addressing unmet medical needs. GBS has previously secured three US patents targeting conditions like Parkinson's and pain, with additional patents pending both domestically and internationally. The company seeks to leverage its extensive intellectual property to create optimized therapeutic mixtures.
GB Sciences has collaborated with the Universidad de Sevilla to publish a paper on terpene-containing nanoparticles for pain treatment, featured in Industrial Crops and Products. This study outlines a novel method for developing time-released drug delivery systems for terpenes, which are highly volatile and lipophilic molecules. The patented technology aims to enhance pain relief, addressing the significant health burden of chronic pain in the U.S., estimated between $560 and $650 billion. Currently, animal trials are underway, paving the way for future FDA clinical trials.
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent for its proprietary cannabinoid containing complex mixtures (CCCM™) aimed at treating chronic inflammation, a condition costing over $130 billion annually. This development follows a two-year study conducted at Michigan State University, highlighting CCCM™'s potential in treating chronic neuroinflammation linked to disorders like HIV-Associated Neurocognitive Disorder, Parkinson's, and Alzheimer's. The company is expanding its intellectual property portfolio, with multiple applications pending both in the U.S. and internationally.
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent for its proprietary cannabinoid containing complex mixtures (CCCM™) aimed at treating Cytokine Storm Syndromes and acute respiratory distress syndrome (ARDS) in COVID-19 patients. The CCCM™ targets specific cytokines to mitigate inflammation while preserving immune responses essential for fighting infections. With a growing demand for innovative anti-inflammatory therapies amid the COVID-19 pandemic, these CCCM™ represent a significant advancement. GBS currently holds four issued patents and has multiple applications pending worldwide.
FAQ
What is the current stock price of GB Sciences (GBLX)?
What is the market cap of GB Sciences (GBLX)?
